To include your compound in the COVID-19 Resource Center, submit it here.

Sarepta gains on Phase I/II data for exon 53 DMD candidate

Sarepta Therapeutics Inc. (NASDAQ:SRPT) jumped $5.65 (14%) to $46.73 on Wednesday and ended the day with a market cap of just over $3 billion after reporting

Read the full 263 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE